Premium
Pasithea Therapeutics Corporation (KTTA)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly tre... Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses. Show more
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities (DLTs) observed to date -- -- No rash observed to date -- MIAMI, Nov. 20...
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...
-- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- No...
MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...
SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”) a clinical-stage biotechnology company...
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and...
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.12 | 4.41176470588 | 2.72 | 2.99 | 2.37 | 18810 | 2.64176718 | CS |
| 4 | -0.36 | -11.25 | 3.2 | 3.3 | 2.37 | 20921 | 2.86191639 | CS |
| 12 | -3.2 | -52.9801324503 | 6.04 | 6.1499 | 2.37 | 54709 | 4.27465249 | CS |
| 26 | -2.36 | -45.3846153846 | 5.2 | 7.5 | 2.37 | 478734 | 5.74842492 | CS |
| 52 | -2.558 | -47.3879214524 | 5.398 | 9.4 | 2.37 | 258518 | 5.8545194 | CS |
| 156 | -26.76 | -90.4054054054 | 29.6 | 47.6 | 2.37 | 563991 | 21.721366 | CS |
| 260 | -77.16 | -96.45 | 80 | 170 | 2.37 | 881498 | 52.3221764 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
